Most libido drugs work on plumbing. PT-141 works on the brain. That single distinction is why bremelanotide, the peptide behind it, became one of the most talked about and most misunderstood molecules in sexual medicine. It is FDA-approved, sitting in a sterile autoinjector under the brand name Vyleesi. It is also sold in shady corners of the internet as a research chemical with no quality control at all. Both things are true, and that gap is exactly what you need to understand before you go near it.

What is PT-141 (bremelanotide) and does it boost libido?

PT-141, or bremelanotide, is a synthetic peptide that activates melanocortin receptors in the brain to increase sexual desire. The FDA approved it in 2019 (as Vyleesi) to treat low libido in premenopausal women with hypoactive sexual desire disorder. In trials it modestly raised desire and lowered distress versus placebo. It is not approved for men.

How does bremelanotide actually work in the body?

Here is the part that makes PT-141 genuinely different from the household names. Viagra and its cousins are vasodilators: they relax blood vessels so blood flows where you want it. They do nothing for the part of desire that lives between your ears. If the want is not there, more blood flow does not manufacture it.

Bremelanotide takes the opposite route. It is derived from alpha-melanocyte-stimulating hormone (alpha-MSH), and it acts as an agonist at melanocortin receptors, primarily the MC4 receptor (MC4R) in the hypothalamus and limbic system (Bremelanotide review, NCBI PMC8788464). These are the brain circuits that govern motivation and sexual interest. In plain terms, it targets the upstream signal, the desire itself, rather than the downstream hardware. The FDA’s own approval language is refreshingly honest here: the agency notes the precise mechanism by which it improves desire is not fully understood, even though the receptor target is known (Drugs.com FDA approval history).

If you want a primer on why peptides keep showing up in this category, our overview at peptides explained covers the basics of how these short amino acid chains signal in the body.

What does the clinical evidence say about PT-141 and desire?

This is where hype meets the data, and the data asks you to stay calm. The approval rested on two large identical Phase 3 trials known as RECONNECT, which together randomized 1,267 premenopausal women with hypoactive sexual desire disorder to bremelanotide 1.75 mg injected under the skin as needed, or placebo, over 24 weeks (RECONNECT Phase 3 trials, NCBI PMC6819021).

The results were statistically significant but modest in absolute size. On the desire domain of the Female Sexual Function Index, women on bremelanotide improved by 0.35 points more than placebo (P less than 0.001). On the distress measure, scores dropped 0.33 points more than placebo (P less than 0.001). Translated by the FDA into something a person can picture: about 25 percent of women on the drug had a meaningful increase in their sexual desire score, versus about 17 percent on placebo (Drugs.com FDA approval history).

Read that twice. It helped, but it was not a switch that flipped desire back on for everyone. A large share of women felt no clear benefit, and the placebo effect in sexual medicine is famously strong. Anyone selling PT-141 as a guaranteed libido rocket is selling past the evidence.

Can men use PT-141 for libido or erectile dysfunction?

Officially, no. Vyleesi is approved only for premenopausal women with acquired, generalized HSDD (FDA approval announcement, PR Newswire). There is no FDA-approved bremelanotide product for men, for erectile dysfunction, or for any male libido indication.

That has not stopped a brisk grey market. Earlier-stage research did study bremelanotide in men, and clinics and online vendors now market it off-label or as an unapproved research chemical. The honest framing: any use in men is off-label or outright unregulated, the dosing is not standardized, and the product quality from a research-chemical vendor is unverified. You are not getting the sterile, tested autoinjector the FDA reviewed. You are getting a vial from a supply chain no one is policing.

What are the side effects and safety risks of bremelanotide?

The side effect profile is the reason PT-141 is taken as needed rather than daily, and it is not trivial. In the prescribing information, nausea topped the list, reported by roughly 40 percent of patients across the trials, compared with about 1 percent on placebo (Vyleesi FDA prescribing information). About 13 percent needed anti-nausea medication, and around 8 percent stopped the drug because of it. For most who continued, the nausea eased after the second dose.

Other common reactions included flushing, injection site reactions, headache, and vomiting. Two issues deserve special attention:

  • Blood pressure and heart rate. Each dose can transiently raise blood pressure and slow heart rate. Because of this, the label does not recommend bremelanotide for people at high cardiovascular risk, and clinicians are told to confirm blood pressure is well controlled first (Vyleesi FDA prescribing information).
  • Skin darkening (hyperpigmentation). About 1 percent of patients developed focal hyperpigmentation, sometimes on the face, gums, or breasts. Risk was higher with darker skin and with daily dosing, and the discoloration did not always resolve after stopping (Vyleesi FDA prescribing information). This is a known class effect of melanocortin agonists, since the same receptor family influences pigmentation.

The approved dosing caps usage deliberately: no more than one dose in 24 hours and no more than eight doses per month (FDA approval announcement, PR Newswire). Those limits exist for a reason. Grey-market users chasing bigger effects with bigger or more frequent doses are wandering off the map the safety data was built on.

How is Vyleesi taken?

It is a subcutaneous injection given on demand. Patients inject under the skin of the abdomen or thigh at least 45 minutes before anticipated sexual activity, then judge their own optimal timing based on how long the benefit lasts and how their stomach handles it (FDA approval announcement, PR Newswire). It is event-driven, not a pill you take every morning, which suits the way desire actually shows up in real life.

The honest bottom line

PT-141 is a legitimately novel idea: a libido treatment that works on the brain’s desire circuitry instead of blood flow. For premenopausal women with diagnosed HSDD, the FDA-approved version is a real, if modest, option worth discussing with a clinician. For everyone else, especially men buying research-chemical vials online, the picture is murkier: no approval, no standardized dosing, no quality assurance, and real side effects involving blood pressure and skin pigmentation. The molecule is interesting. The marketing around it usually runs well ahead of the science.

Frequently asked questions

Is PT-141 the same as bremelanotide?

Yes. PT-141 is the developmental name for bremelanotide, the same peptide sold as the FDA-approved drug Vyleesi for low sexual desire in premenopausal women.

How long does PT-141 take to work?

For the approved Vyleesi product, patients are instructed to inject at least 45 minutes before anticipated sexual activity, then find their own optimal timing based on duration of benefit and side effects.

Is PT-141 approved for men?

No. Bremelanotide is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Any use in men is off-label or via unregulated research-chemical products, with no standardized dosing or quality assurance.

What is the most common side effect of bremelanotide?

Nausea, reported by roughly 40 percent of patients in the prescribing information, versus about 1 percent on placebo. Around 8 percent stopped the drug because of it, though it often eased after the second dose.

Does PT-141 work better than Viagra?

They do different jobs. Viagra increases blood flow for erections, while bremelanotide targets brain pathways for desire. They are not interchangeable, and bremelanotide’s trial benefit over placebo was modest, not dramatic.

Medical disclaimer: This article is for general information only and is not medical advice. Bremelanotide affects blood pressure and is not suitable for everyone. Talk to a qualified clinician before considering it, and do not use unapproved research-chemical products.